Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.
Shah S, Nandy RK, Sethi SS, Chavan B, Pathak S, Dutta S, Rai S, Singh C, Chayal V, Patel C, Kumar NR, Chavan AT, Chawla A, Singh A, Roy AK, Singh N, Baik YO, Lee Y, Park Y, Jeong KH, Ahmed S.
Shah S, et al. Among authors: singh n, singh c, singh a.
Lancet Reg Health Southeast Asia. 2023 Aug 24;19:100256. doi: 10.1016/j.lansea.2023.100256. eCollection 2023 Dec.
Lancet Reg Health Southeast Asia. 2023.
PMID: 38076719
Free PMC article.